Express News | IDEAYA Announces First-Patient-in for Phase 1 Clinical Trial Evaluating Ide161 in Combination With Keytruda® (Pembrolizumab) in Patients With Endometrial Cancer

ReutersDec 10 06:00 ET

IDEAYA Biosciences Nominates IDE892 as Development Candidate

MT NewswiresDec 9 08:33 ET

Express News | IDEAYA Biosciences Inc -Ind-Enabling Studies Ongoing and Targeting Ind-Filing for Ide892 in Mid-2025

ReutersDec 9 06:06 ET

Express News | IDEAYA Biosciences Announces Development Candidate Nomination of Ide892, a Potential Best-in-Class Mta-Cooperative Prmt5 Inhibitor

ReutersDec 9 06:06 ET

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

PR NewswireDec 2 06:00 ET

Express News | IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 29 06:00 ET